Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetics) is a biopharmaceutical company focused on the discovery and development of pharmaceutical products for the treatment of human diseases, including immunology, metabolism, cardiology, and ophthalmology. The company's pipeline includes LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211, which has completed Phase II clinical trials for the treatment of type 2 diabetes; LX2931, in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032, which has completed Phase II clinical trials for the treatment of symptoms associated with carcinoid syndrome. It also has a preclinical development candidate, LX7101, for the treatment of glaucoma.